🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Glyoxalase 1 (Glo1) inducer

    United Therapeutics Europe Ltd

    Glucose Intolerance

    phase 2 other completed

    1 trial

  2. Golexanolone Placebo Capsules, oral capsules, soft, GR3027 10 mg

    COGNITION THERAPEUTICS INC

    Primary biliary cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  3. Golimumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo for Guselkumab, Golimumab and JNJ-78934804, JNJ-78934804

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  4. Granexin® gel (200 μM)

    United Therapeutics Europe Ltd

    Second Degree Burn

    phase 2 small molecule terminated

    1 trial

  5. Green tea

    United Therapeutics Europe Ltd

    Lung Cancer Prevention

    phase 2 other completed

    1 trial

  6. Group A FMP2.1/AS01B

    United Therapeutics Europe Ltd

    Malaria

    phase 2 mab completed

    1 trial

  7. Guselkumab

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 2 mab active

    1 trial

  8. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo to Guselkumab and Golimumab and JNJ-78934804, Golimumab, JNJ-78934804

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  9. HB-adMSC

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 mab terminated

    1 trial

  10. HMB-001

    Hemab Therapeutics Holdings

    Glanzmann Thrombasthenia

    phase 2 small molecule active

    1 trial

  11. HMB-001

    Hemab Therapeutics Holdings

    Glanzmann Thrombasthenia

    phase 2 small molecule active

    1 trial

  12. HMB-002 (Part A)

    Hemab Therapeutics Holdings

    Von Willebrand Disease (VWD)

    phase 2 small molecule active

    1 trial

  13. HPV DNA Plasmids Therapeutic Vaccine VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Anal Intraepithelial Neoplasia

    phase 2 mab completed

    1 trial

  14. HT-001 2% Topical Gel

    Hoth Therapeutics

    Acneiform Eruption Due to Chemical

    phase 2 small molecule active

    1 trial

  15. HT-001, HT-001, The corresponding placebo is formulated using the same excipients as HT-001 and is identical in color and physical appearance., HT-001

    Hoth Therapeutics

    Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors

    phase 2 small molecule active

    1 trial

  16. HTNV/PUUV DNA vaccine

    United Therapeutics Europe Ltd

    Hemorrhagic Fever With Renal Syndrome

    phase 2 mab completed

    1 trial

  17. HTX-011A

    Heron Therapeutics

    Postoperative Pain

    phase 2 small molecule completed

    1 trial

  18. HTX-011B

    Heron Therapeutics

    Postoperative Pain

    phase 2 small molecule completed

    1 trial

  19. HTX-034

    Heron Therapeutics

    Bunions

    phase 2 small molecule completed

    1 trial

  20. HYDROXYCARBAMIDE , BEVACIZUMAB , SUNITINIB , OCTREOTIDE , EVEROLIMUS , Lutathera 370 MBq/mL solution for infusion

    Ningbo Cancer Hospital

    Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)

    phase 2 small molecule active

    1 trial

  21. Halneuron

    Dogwood Therapeutics

    Chemotherapy Induced Neuropathic Pain

    phase 2 small molecule active

    1 trial

  22. Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co

    Boehringer Ingelheim

    gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. Herombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

  24. Herzuma

    Vera Therapeutics

    HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources